MarginsXMarginsX
Home › Markets › Health Care › DMAC

DiaMedica Therapeutics Inc. (DMAC)

DMAC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.33
-5.23% on the day
Market cap
$449.5M
Small cap
Revenue
No annual revenue filed since the period ending 2018-12-31
Net income
No annual revenue filed since the period ending 2018-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerDMAC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001401040
SEC industry codePharmaceutical Preparations
Incorporated inCanada

Financials

No annual revenue filed since the period ending 2018-12-31.

Warning signs

Cash runway
2.4 months
$6.8M cash at September 30, 2026
Share count, 1 year
+3.6%
2025-11-10 to 2026-11-09 · +42.2% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$7.6M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors, among others, raise substantial doubt about our ability to continue operations as a going concern which is not alleviated."
10-Q 2026-11-12
Cash and burn$6.8M cash; operating cash flow -$8.4M a quarter.Report 2026-09-30
Shares outstanding53,957,474 (2026-11-09); 52,077,439 a year earlier; 37,953,711 three years earlier.Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBaker Tilly US, LLP, Minneapolis, Minnesota, United StatesPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $7.6M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$11.3M-$8.8M$6.8MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$10.1M-$8.1M$5.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$10.0M-$9.1M$4.9MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$8.7M-$7.8M$15.6MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$8.6M-$6.5M$3.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$7.7M-$7.6M$4.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$7.7M-$7.1M$2.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$7.9M-$6.4M$3.0MNo debt tagsNeeds four quarters10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B2
424B22025-08-22
Latest annual report
FORM 10-K
10-K2026-03-30
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxy
FORM DEFA14A
DEFA14A2026-04-01

Source: SEC EDGAR submissions feed, 429 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.1%
1 month+12.4%
3 months+30.2%
Year to date+10.4%
1 year+62.2%
From 52-week high-18.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
MPLTMapLight Therapeutics Inc.$6.90-4.83%$446.9M
OVIDOvid Therapeutics Inc.$2.40-5.51%$453.0M
ARVNArvinas Inc.$6.77-0.73%$443.3M
EOLSEvolus Inc.$6.63-4.74%$438.8M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
KMDAKamada Ltd.$8.11+0.25%$468.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier